Tele: 561.316.3330
Breaking Medical Device News

Monday, September 27, 2021
HomeEXECUTIVESLaura Niklason MD, Ph.D Appointed Humacyte President & Chief Executive Officer: Involved In All Aspects of Growth Including Scientific Innovation & Development, Financing, Clinical Trials and More

Laura Niklason MD, Ph.D Appointed Humacyte President & Chief Executive Officer: Involved In All Aspects of Growth Including Scientific Innovation & Development, Financing, Clinical Trials and More

November 20, 2020

Laura Niklason, MD, Ph.D. is a world leader in tissue engineering and cellular therapies, founded Humacyte in 2004.

Laura Niklason, MD has been deeply involved in all key aspects of Humacyte’s growth, including scientific innovation and development, financing, clinical trials, manufacturing and the development and management of strategic partnerships. She led the first human implant of Humacyte’s human acellular vessel (HAV) in 2013. In taking on the CEO role at Humacyte,

Laura Niklason, MD will depart her role as the Vice-Chair of Anesthesiology at Yale University. Among Dr. Niklason’s many accomplishments, she was cited by Time for creating one of the 50 Best Inventions of 2010, was inducted into the National Academy of Inventors, the National Academy of Medicine, the National Academy of Engineering and Women in Technology Hall of Fame, and named by Fortune magazine as one of 34 Leaders Who are Changing Health Care.

In addition, Jeffrey Lawson MD, Ph.D. has been appointed the newly established role of Chief Surgical Officer and Vice-Chairman.

“Jeff is an inspiring leader in the organization and our industry. The Company is enriched by his enthusiasm, passion, and grit, and I look forward to continuing our decades of collaboration as he takes responsibility for expanding and accelerating our clinical applications and pathways,” said Dr. Niklason. “Humacyte has been my life’s work, and I look ahead with excitement and purpose at our potential to improve the lives of many patients. I’m grateful to our Board of Directors for the trust they’ve placed in me to lead the Humacyte team toward realizing the full extent of our revolutionary regenerative therapies.”

Dr. Lawson will serve as the Company’s first Chief Surgical Officer, a new role established to drive Humacyte’s clinical adoption and medical innovation. He will be Humacyte’s primary interface with the global surgical community, including physicians and surgeons around the world. Dr. Lawson will also seek to advance the use of Humacyte’s HAV under Food and Drug Administration (FDA) Compassionate Use authorization of the product and to assist with Phase III pivotal trials intended to support a Biologics License Application under the FDA’s Fast Track designation with Accelerated Approval and Priority Review.

“Humacyte’s success reflects Laura’s pioneering vision. As long-time collaborators, I look forward to continuing to work in support of that vision to improve the lives of patients,” said Dr. Lawson. “Taking on the new role of Chief Surgical Officer provides a unique opportunity to expand on key relationships with the surgical community and with strategic partners, such as the Department of Defense, and to further Humacyte’s aggressive growth agenda.”

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

ProSomnus® Sleep Technologies Adds John E. Remmers, MD, to Leadership Team

Dr. John E. Remmers will provide expert medical and strategic guidance on a range of initiatives, including research and development, regulatory clearances, company strategy, medical education, and clinical investigations.

Nanox to Announce Zebra Medical Vision Secures 8th 510K FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

On August 10th, 2021 Nanox announced that it had entered into an acquisition agreement via merger with Zebra Medical Vision LTD.

Christopher Joyce Joins Miach Orthopaedics as VP & CFO

Christopher Joyce has joined as vice president and chief financial officer, and Kevin Sidow has been appointed to the company’s board of directors.

NGMedical GmbH Receives FDA Clearance for Its AM Titanium Lumbar Interbody BEE® PLIF

The BEE® PLIF cage has been created to benefit from additive manufacturing features. The purposefully designed honeycomb endplate design reduces the risk of subsidence, while allowing fusion.

Recombinant Technologies is Raising Capital to Roll Out a Game Changing Alzheimer’s Treatment

Recombinant Technologies is focused on treating the root cause of Alzheimer's Disease delivering a huge improvement in the quality of life of those afflicted.

Tyber Medical Reaches Agreement to Acquire CatapultMD

Once the acquisition is complete, Tyber Medical will own and operate a combined 100,000-square feet of manufacturing space between its Pennsylvania headquarters and Florida-based facilities.

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

By using this website you agree to accept Medical Device News Magazine Privacy Policy